Compare · CVM vs RVMD
CVM vs RVMD
Side-by-side comparison of Cel-Sci Corporation (CVM) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CVM and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $39.58B, about 1935.5x CVM ($20.4M).
- Over the past year, CVM is down 73.9% and RVMD is up 384.6% - RVMD leads by 458.5 points.
- CVM has been more active in the news (5 items in the past 4 weeks vs 3 for RVMD).
- RVMD has more recent analyst coverage (25 ratings vs 0 for CVM).
- Company
- Cel-Sci Corporation
- Revolution Medicines Inc.
- Price
- $1.16+2.21%
- $186.14+3.91%
- Market cap
- $20.4M
- $39.58B
- 1M return
- +13.79%
- +18.88%
- 1Y return
- -73.87%
- +384.61%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- AMEX
- NASDAQ
- IPO
- 1997
- 2020
- News (4w)
- 5
- 3
- Recent ratings
- 0
- 25
Cel-Sci Corporation
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest CVM
- CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer
- SEC Form DEF 14A filed by Cel-Sci Corporation
- Chief Scientific Officer Talor Eyal was granted 2,307 shares, increasing direct ownership by 33% to 9,318 units (SEC Form 4)
- Chief Financial Officer Prichep Patricia B was granted 4,125 shares, increasing direct ownership by 31% to 17,489 units (SEC Form 4)
- Chief Executive Officer Kersten Geert R was granted 5,192 shares, increasing direct ownership by 2% to 216,142 units (SEC Form 4)
- CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care
- Cel-Sci Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- CEL-SCI Announces Closing of Offering
- CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy
- SEC Form 424B5 filed by Cel-Sci Corporation
Latest RVMD
- European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
- Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
- Director Patel Sushil exercised 2,955 shares at a strike of $37.54 and sold $1,048,967 worth of shares (5,580 units at $187.99) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 21,656 units (SEC Form 4)
- Chief Financial Officer Anders Jack exercised 20,000 shares at a strike of $18.56 and sold $3,366,604 worth of shares (20,000 units at $168.33) as part of a pre-agreed trading plan (SEC Form 4)
- Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
- Director Kim Lorence H. was granted 1,191 shares, increasing direct ownership by 2% to 74,281 units (SEC Form 4)
- Director Borisy Alexis was granted 1,191 shares, increasing direct ownership by 0.05% to 2,340,075 units (SEC Form 4)
- Director Anderson Elizabeth M was granted 1,191 shares, increasing direct ownership by 14% to 9,406 units (SEC Form 4)
- Director Horning Sandra was granted 1,191 shares, increasing direct ownership by 1% to 97,765 units (SEC Form 4)
- Director Clyburn Frank was granted 1,191 shares, increasing direct ownership by 12% to 10,929 units (SEC Form 4)